Ryan Gentzler is an Oncology physician affiliated with University of Virginia Health System. OpenAlex indexes 152 publications with 4,382 citations (h-index 26); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1240 Lee St
Charlottesville, VA 229080001
Telephone
434-924-9333Provider last certified this registry record 9 Aug 2023.
Clinical trials
- Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Sponsor: Ryan Gentzler, MD
- Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.6%Kinase inhibitor31.6%Tagrisso84%Alecensa16%Part D<11 patientsMetabolism & gastrointestinal
18.1%Serotonin-3 Receptor Antagonist18.1%Ondansetron Hcl100%Part D≥31 patientsNervous system
17.7%Phenothiazine13.1%Prochlorperazine Maleate100%Part D≥26 patientsOpioid Agonist4.6%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Frederick Hayden, MD
University of Virginia Health System
Allan Tsung, MD
University of Virginia Health System
Irving Kron, MD
University of Virginia Health System
Karen Ballen, MD
University of Virginia Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”